<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00081328</url>
  </required_header>
  <id_info>
    <org_study_id>IND - DK61230-TODAY</org_study_id>
    <nct_id>NCT00081328</nct_id>
  </id_info>
  <brief_title>Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY)</brief_title>
  <acronym>TODAY</acronym>
  <official_title>Studies to Treat Or Prevent Pediatric Type 2 Diabetes (STOPP-T2D) Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY) Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National
      Institutes of Health (NIH) has sponsored a consortium of investigators to conduct a clinical
      treatment trial, Treatment Options for type 2 Diabetes in Adolescents and Youth (TODAY).

      The primary objective of the TODAY trial is to compare the efficacy of three treatment arms
      on time to treatment failure based on glycemic control. The secondary aims are to:

        -  compare and evaluate the safety of the three treatment arms;

        -  compare the effects of the three treatments on the pathophysiology of type 2 diabetes
           (T2D) with regards to beta cell function and insulin resistance, body composition,
           nutrition, physical activity and aerobic fitness, cardiovascular risk factors,
           microvascular complications, quality of life, and psychological outcomes;

        -  evaluate the influence of individual and family behaviors on treatment response; and

        -  compare the relative cost effectiveness of the three treatment arms.

      The three treatment regimens are: (1) metformin alone, (2) metformin plus rosiglitazone, and
      (3) metformin plus an intensive lifestyle intervention called the TODAY Lifestyle Program
      (TLP). The study recruits patients over a three-year period and follows patients for a
      minimum of two years. Patients are randomized within two years of the diagnosis of T2D.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      T2DM has dramatically increased throughout the world in many ethnic groups and among people
      with diverse social and economic backgrounds. Over the last decade, the increase in the
      number of children and youth with T2DM has been labeled an &quot;epidemic&quot;. Before the 1990s, it
      was rare for most pediatric centers to have patients with T2DM. By 1994, T2DM patients
      represented up to 16% of new cases of diabetes in children in urban areas, and by 1999,
      depending on geographic location, the range of percent of new cases due to T2DM was between
      8-45% and disproportionately represented in minority populations.

      T2DM in children and youth, as in adults, is due to the combination of insulin resistance and
      relative β-cell failure. It appears that there are a host of genetic and environmental risk
      factors for insulin resistance and limited β-cell reserve. The epidemic of pediatric T2DM is
      coincident with the rise in the number of children who are overweight or at risk for
      overweight and with a decrease in the physical activity pattern of youth. There has been a
      strong association between T2DM and the onset of puberty, a positive family history of T2DM,
      and elements of the metabolic syndrome such as acanthosis nigricans and polycystic ovarian
      syndrome (PCOS).

      Preceding the development of frank diabetes, children and youth experience a period of
      prediabetes. Prediabetes is defined as either elevated fasting glucose or impaired glucose
      tolerance. Despite the dramatic increase in the number of cases of prediabetes and T2DM in
      pediatric populations, there have been no published large-scale studies investigating the
      pathophysiology, treatment, and complications of these disorders in children and youth. The
      long-term complications and costs associated with T2DM make such studies imperative. Between
      1997 and 2002, the estimated cost of diabetes with regard to direct medical cost increased
      from $44 billion to $92 billion, and the total cost increased from $98 billion to $132
      billion. The vast majority of monies are spent on the long-term complications of this
      disorder. Since the long-term microvascular and cardiovascular complications relate to
      duration of diabetes and to control of glycemia, it could be hypothesized that the increasing
      number of children and youth diagnosed with T2DM, if not effectively treated, could
      dramatically add to the economic burden of this disease over the ensuing decades.

      Except in American Indian youth, there are no population-based data available with regard to
      prevalence of T2DM. Instead, only clinic-based reports indicate that there has been a
      tremendous increase in the number of children and adolescents with T2DM. T2DM occurs almost
      exclusively in children and youth who are overweight or at risk for overweight (BMI &gt; 85th
      percentile for age). At the time of diagnosis, most pediatric patients are in the midst of
      Tanner Stage 2-4 puberty. Puberty contributes to insulin resistance due to augmentation of
      growth hormone secretion, and if these normal pubertal physiologic changes are not
      compensated for by increased insulin secretion, frank diabetes will develop. Half to
      three-quarters of patients have a parent and close to ninety percent have at least one first
      or second degree relative with T2DM. The clinical presentation of T2DM in youth ranges from
      mild asymptomatic hyperglycemia to severe ketoacidosis. In those who present with clinical
      symptoms due to hyperglycemia, glycosuria and weight loss are present in 20-40%, ketonuria is
      present in 33% and ketoacidosis is found in 5-10%. Patients without clinical symptoms are
      diagnosed as the result of routine blood or urine testing during a health care visit or by
      investigating a variety of complaints such as chronic infection, sleep apnea, hyperlipidemia,
      hypertension, and hirsutism or irregular periods associated with PCOS. It may be difficult to
      distinguish T1DM from T2DM at presentation. The absence of autoantibodies is a prerequisite
      for the diagnosis of T2DM. In addition, evidence of residual insulin secretion is suggestive
      of T2DM rather than T1DM.

      Patients with T2DM have dual abnormalities of insulin resistance and insulin deficiency. It
      is hypothesized that to achieve the level of glycemic control required to optimize long-term
      outcome and decrease or prevent microvascular complications, treatment regimens should
      theoretically be designed to improve insulin resistance and preserve residual β-cell
      function. The available anti-diabetic agents have not been adequately evaluated in pediatric
      patients. This is particularly relevant with regard to using combination therapy to improve
      glycemic control or lifestyle interventions aimed at obesity and sedentary behavior.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2004</start_date>
  <completion_date type="Actual">February 2014</completion_date>
  <primary_completion_date type="Actual">February 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment Failure (Loss of Glycemic Control)</measure>
    <time_frame>Study duration - 2 years to 6.5 years of follow up from randomization</time_frame>
    <description>Defined as A1c persistently &gt;=8% over a 6-month period or persistent metabolic decompensation (inability to wean insulin within 3 months of initiation or the occurrence of a second episode within three months of discontinuing insulin)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Insulin Sensitivity</measure>
    <time_frame>24 months</time_frame>
    <description>All participants were followed to 24 months. Insulin sensitivity is measured from OGTT as inverse of fasting insulin (mL/uU). The analysis sample includes only participants with 24 month data who had not experienced the primary outcome by that time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <time_frame>Reported as occurred during study follow-up - 2 years to 6.5 years from randomization.</time_frame>
    <description>Number of serious adverse events reported during the trial. Participant could have multiple episodes reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin Secretion</measure>
    <time_frame>24 months</time_frame>
    <description>Insulinogenic index determined from OGTT as difference in insulin at 30 minutes minus 0 minutes divided by difference in glucose at 30 minutes minus 0 minutes. The analysis sample includes only participants with 24 month data who had not experienced the primary outcome by that time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body Composition -- BMI</measure>
    <time_frame>24 months</time_frame>
    <description>Body mass index (BMI) measured in kg per meters squared. The analysis sample includes only participants with 24 month data who had not experienced the primary outcome by that time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body Composition -- Waist Circumference</measure>
    <time_frame>24 months</time_frame>
    <description>Waist circumference (cm) measured at the iliac crest at its outermost point with the measuring tape placed around the participant in a horizontal plane parallel to the floor at the mark and the measurement teken at the end of normal expiration without the tape compressing the skin. The analysis sample includes only participants with 24 month data who had not experienced the primary outcome by that time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body Composition -- Bone Density</measure>
    <time_frame>24 months</time_frame>
    <description>Measured by DXA, both whole body scan and AP-spine scan. The analysis sample includes only participants with 24 month data who had not experienced the primary outcome by that time. In addition, in about 1/3 of participants DXA scans could not be obtained on participants weighing more than 300 pounds (136 kg), the upper limit in size set by the machine manufacturers. Scans were considered invalid if a body part (e.g., arm, leg) was completely off or partially off the scanner, there was hand-hip overlap, or there was motion or movement during the scan.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body Composition -- Fat Mass</measure>
    <time_frame>24 months</time_frame>
    <description>Determined by DXA whole body scan. The analysis sample includes only participants with 24 month data who had not experienced the primary outcome by that time. In addition, in about 1/3 of participants DXA scans could not be obtained on participants weighing more than 300 pounds (136 kg), the upper limit in size set by the machine manufacturers. Scans were considered invalid if a body part (e.g., arm, leg) was completely off or partially off the scanner, there was hand-hip overlap, or there was motion or movement during the scan.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comorbidity -- Hypertension</measure>
    <time_frame>Data collected at baseline and during follow-up - 2 years to 6.5 years from randomization.</time_frame>
    <description>A diagnosis was made by an out-of-range value &gt;=95th percentile or systolic &gt;=130 or diastolic &gt;=80 sustained over 6 months or on an anti-hypertensive medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comorbidity -- LDL Dyslipidemia</measure>
    <time_frame>Data collected at baseline and during follow-up - 2 years to 6.5 years from randomization.</time_frame>
    <description>A diagnosis was made from out-of-range value &gt;= 130 mg/dL sustained over 6 months or put on lipid lowering medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comorbidity -- Triglycerides Dyslipidemia</measure>
    <time_frame>Data collected at baseline and during follow-up - 2 years to 6.5 years from randomization.</time_frame>
    <description>A diagnosis was made by an out-of-range value &gt;=150 mg/dL sustained over 6 months or on appropriate lipid lowering medication.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">699</enrollment>
  <condition>Diabetes Mellitus, Type II</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Metformin alone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Metformin + Rosiglitazone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Metformin + Lifestyle Program</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>capsule, 1000 mg bid</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosiglitazone</intervention_name>
    <description>capsule, 4 mg bid</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Lifestyle Program</intervention_name>
    <description>a lifestyle change (LC) phase of weekly sessions for months 1-6, followed by a bi-weekly lifestyle maintenance (LM) phase through months 7-12, and a continued contact (CC) phase from months 13 through the end of the study. The CC phase sessions are scheduled monthly for the initial 12 months (study months 13-24) and then quarterly or 4 times a year to the end of the study</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria (during Screening and Run-in period):

          -  Diabetes by ADA criteria (laboratory determinations of fasting glucose ≥ 126 mg/dL,
             random glucose ≥ 200 mg/dL, or two-hour OGTT glucose ≥ 200 mg/dL) documented and
             confirmed in medical record. For patients diagnosed with diabetes during screening who
             have a normal fasting glucose but an elevated two-hour glucose during an OGTT, the
             HbA1c must be ≥ 6%.

          -  Duration since diagnosis less than two years by date of randomization.

          -  BMI ≥ 85th percentile documented at time of diagnosis or at screening.

          -  Fasting C-peptide at screening (drawn at least one week after treatment for ketosis or
             acidosis, if applicable) &gt; 0.6 ng/mL.

          -  Absence of pancreatic autoimmunity (both GAD and ICA512 negative).

          -  Age 10-17, with randomization prior to 18th birthday.

          -  Signed informed consent/assent forms for the pre-randomization period.

          -  A family member or adult closely involved in the daily activities of the child agrees
             to participate in the child's treatment.

          -  Fluency in English or Spanish for both child and family member.

          -  Patient and family able to fully participate in trial protocol in the opinion of the
             investigator.

        Exclusion Criteria (during Screening and Run-in period):

          -  Participating in another interventional research study protocol in the past 30 days.

          -  Genetic syndrome or disorder known to affect glucose tolerance other than diabetes.

          -  Patient on inhaled steroids at dose above 1000 mcg daily Flovent equivalent.

          -  Patient on a course of oral steroids within the last 60 days or on oral steroids more
             than 20 days during the past year.

          -  Patient on medication(s) that are known to affect insulin sensitivity or secretion
             within the last 30 days.

          -  Patient on medication(s) that are known to cause weight gain within the last 30 days.

          -  Patient on any weight-loss medication(s) within the last 30 days.

          -  Patient on medication(s) known to affect the metabolism of study drug.

          -  Inability to comprehend the lowest grade level at which lifestyle intervention
             materials are prepared, for both child and participating family member.

          -  Females who are pregnant, planning to become pregnant within two years of enrollment,
             or who admit sexual activity without appropriate contraception.

          -  Calculated creatinine clearance &lt; 70 mL/min.

          -  Any transaminase &gt; 2.5 ULN. If any transaminase 1.5-2.5 times ULN, then patient must
             be appropriately evaluated by PCP (minimum evaluation includes ceruloplasmin level,
             alpha-1 antitrypsin phenotype, ANA, anti-smooth muscle antibody, anti-LKM antibody,
             anti-HCV, and anti-HBc total antibody not IgM, iron, and TIBC) and is eligible if all
             other causes for elevation are ruled out and it is presumed due only to non-alcoholic
             fatty liver disease (NAFLD).

          -  Diabetic ketoacidosis (DKA) at any time after diagnosis unless only a single episode
             of DKA related to a significant medical illness.

          -  Physical limitations preventing patient from being randomized to the lifestyle
             intervention.

          -  Patient plans to leave the geographic area within one calendar year.

          -  Abnormal reticulocyte count or HbA1c chromatogram at time of screening.

          -  Admitted use of anabolic steroids within the past 60 days.

          -  Other significant organ system illness or condition (including psychiatric or
             developmental disorder) that would prevent participation in the opinion of the
             investigator.

          -  Patient participates in a formal weight-loss program.

        Inclusion Criteria (post Run-in and Randomization):

          -  Duration since diagnosis less than 2 years at randomization.

          -  HbA1c &lt; 8% on metformin alone.

          -  Age 10-17, with randomization before patient is 18 years old.

          -  Signed consent/assent forms for randomization and the post-randomization phase.

          -  A family member or adult closely involved in the daily activities of the child agrees
             to participate in the child's treatment.

          -  Fluency in English or Spanish for both child and family member.

          -  Patient and family able to fully participate in trial protocol in the opinion of the
             investigator.

        Exclusion Criteria (post Run-in and Randomization):

          -  Refractory hypertension: average systolic blood pressure ≥ 150 mmHg or average
             diastolic blood pressure ≥ 95 mmHg despite appropriate medical therapy.

          -  Refractory hyperlipidemia: total cholesterol &gt; 300 mg/dL or LDL &gt; 190 mg/dL or
             triglycerides &gt; 800 mg/dL, despite appropriate medical therapy.

          -  Refractory anemia: hematocrit &lt; 30% or hemoglobin &lt; 10 gm/dL despite appropriate
             medical therapy.

          -  Patient on a thiazolidinedione (TZD) within the last 12 weeks.

          -  Patient on non-study diabetes medications within the past 6 weeks.

          -  Patient on inhaled steroids at dose above 1000 mcg daily Flovent equivalent.

          -  Patient on a course of oral steroids within the last 60 days or on oral steroids more
             than 20 days during the past year.

          -  Patient on medication(s) that are known to affect insulin sensitivity or secretion
             within the last 30 days.

          -  Patient on medication(s) that are known to cause weight gain within the last 30 days.

          -  Patient on any weight-loss medication(s) within the last 30 days.

          -  Patient on medication(s) known to affect the metabolism of study drug.

          -  Inability to comprehend the lowest grade level at which lifestyle intervention
             materials are prepared, for both child and participating family member, assessed by
             mastery of standard diabetes education program administered during run-in.

          -  Inability to comply with requirements of study during run-in period.

          -  Females who are pregnant, planning to become pregnant within two years of enrollment,
             or who admit sexual activity without appropriate contraception.

          -  Calculated creatinine clearance &lt; 70 mL/min.

          -  Physical limitations preventing patient from being randomized to the lifestyle
             intervention.

          -  Patient plans to leave the geographic area within one calendar year.

          -  Admitted use of anabolic steroids within 60 days.

          -  Other significant organ system illness or condition (including psychiatric or
             developmental disorder) that would prevent participation in the opinion of the
             investigator.

          -  Patient participates in a formal weight loss program.

          -  Episode of DKA during the run-in.30.

          -  Edema at the time of randomization (a participant who experiences edema during run-in
             must have recovered within 2 weeks and be edema free for 1 week prior to
             randomization).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Phil Zeitler, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Colorado, Denver</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kathryn Hirst, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>George Washington University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Hospital Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado Health Sciences Center, The Children's Hospital</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale University</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>George Washington University Biostatistics Center</name>
      <address>
        <city>Rockville</city>
        <state>Maryland</state>
        <zip>20852</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital Diabetes Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Joslin Diabetes Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Louis University Health Sciences Center</name>
      <address>
        <city>St Louis</city>
        <state>Missouri</state>
        <zip>63104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University Department of Pediatrics</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York City</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State University of New York Upstate Medical University</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Case Western Reserve</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Oklahoma</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>93104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Health Science Center at San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://today.bsc.gwu.edu/</url>
    <description>public access to intervention materials used in TODAY</description>
  </link>
  <reference>
    <citation>TODAY Study Group, Zeitler P, Epstein L, Grey M, Hirst K, Kaufman F, Tamborlane W, Wilfley D. Treatment options for type 2 diabetes in adolescents and youth: a study of the comparative efficacy of metformin alone or in combination with rosiglitazone or lifestyle intervention in adolescents with type 2 diabetes. Pediatr Diabetes. 2007 Apr;8(2):74-87.</citation>
    <PMID>17448130</PMID>
  </reference>
  <reference>
    <citation>Songer T, Glazner J, Coombs LP, Cuttler L, Daniel M, Estrada S, Klingensmith G, Kriska A, Laffel L, Zhang P; the TODAY Study Group. Examining the economic costs related to lifestyle and pharmacological interventions in youth with Type 2 diabetes. Expert Rev Pharmacoecon Outcomes Res. 2006 Jun 1;6(3):315-324.</citation>
    <PMID>19774104</PMID>
  </reference>
  <reference>
    <citation>Grey M, Schreiner B, Pyle L. Development of a diabetes education program for youth with type 2 diabetes. Diabetes Educ. 2009 Jan-Feb;35(1):108-16. doi: 10.1177/0145721708325156.</citation>
    <PMID>19244566</PMID>
  </reference>
  <reference>
    <citation>TODAY Study Group. Design of a family-based lifestyle intervention for youth with type 2 diabetes: the TODAY study. Int J Obes (Lond). 2010 Feb;34(2):217-26. doi: 10.1038/ijo.2009.195. Epub 2009 Oct 13. Review.</citation>
    <PMID>19823189</PMID>
  </reference>
  <reference>
    <citation>Larkin ME, McGuigan P, Richards D, Blumenthal K, Milaszewski K, Higgins L, Schanuel J, Long C. Collaborative Staffing Model for Multiple Sites: Reducing the challenges of study coordination in complex, multi-site clinical trials. Appl Clin Trials. 2011 Jan 1;20(1):30-35.</citation>
    <PMID>24955003</PMID>
  </reference>
  <results_reference>
    <citation>Klingensmith GJ, Pyle L, Arslanian S, Copeland KC, Cuttler L, Kaufman F, Laffel L, Marcovina S, Tollefsen SE, Weinstock RS, Linder B; TODAY Study Group. The presence of GAD and IA-2 antibodies in youth with a type 2 diabetes phenotype: results from the TODAY study. Diabetes Care. 2010 Sep;33(9):1970-5. doi: 10.2337/dc10-0373. Epub 2010 Jun 2.</citation>
    <PMID>20519658</PMID>
  </results_reference>
  <results_reference>
    <citation>Copeland KC, Zeitler P, Geffner M, Guandalini C, Higgins J, Hirst K, Kaufman FR, Linder B, Marcovina S, McGuigan P, Pyle L, Tamborlane W, Willi S; TODAY Study Group. Characteristics of adolescents and youth with recent-onset type 2 diabetes: the TODAY cohort at baseline. J Clin Endocrinol Metab. 2011 Jan;96(1):159-67. doi: 10.1210/jc.2010-1642. Epub 2010 Oct 20.</citation>
    <PMID>20962021</PMID>
  </results_reference>
  <results_reference>
    <citation>TODAY Study Group, Wilfley D, Berkowitz R, Goebel-Fabbri A, Hirst K, Ievers-Landis C, Lipman TH, Marcus M, Ng D, Pham T, Saletsky R, Schanuel J, Van Buren D. Binge eating, mood, and quality of life in youth with type 2 diabetes: baseline data from the today study. Diabetes Care. 2011 Apr;34(4):858-60. doi: 10.2337/dc10-1704. Epub 2011 Feb 28.</citation>
    <PMID>21357794</PMID>
  </results_reference>
  <results_reference>
    <citation>Anderson BJ, Edelstein S, Abramson NW, Katz LE, Yasuda PM, Lavietes SJ, Trief PM, Tollefsen SE, McKay SV, Kringas P, Casey TL, Marcus MD. Depressive symptoms and quality of life in adolescents with type 2 diabetes: baseline data from the TODAY study. Diabetes Care. 2011 Oct;34(10):2205-7. doi: 10.2337/dc11-0431. Epub 2011 Aug 11.</citation>
    <PMID>21836107</PMID>
  </results_reference>
  <results_reference>
    <citation>Laffel L, Chang N, Grey M, Hale D, Higgins L, Hirst K, Izquierdo R, Larkin M, Macha C, Pham T, Wauters A, Weinstock RS; TODAY Study Group. Metformin monotherapy in youth with recent onset type 2 diabetes: experience from the prerandomization run-in phase of the TODAY study. Pediatr Diabetes. 2012 Aug;13(5):369-75. doi: 10.1111/j.1399-5448.2011.00846.x. Epub 2012 Feb 27.</citation>
    <PMID>22369102</PMID>
  </results_reference>
  <results_reference>
    <citation>Bacha F, Pyle L, Nadeau K, Cuttler L, Goland R, Haymond M, Levitsky L, Lynch J, Weinstock RS, White NH, Caprio S, Arslanian S; TODAY Study Group. Determinants of glycemic control in youth with type 2 diabetes at randomization in the TODAY study. Pediatr Diabetes. 2012 Aug;13(5):376-83. doi: 10.1111/j.1399-5448.2011.00841.x. Epub 2012 Feb 15.</citation>
    <PMID>22332798</PMID>
  </results_reference>
  <results_reference>
    <citation>TODAY Study Group, Zeitler P, Hirst K, Pyle L, Linder B, Copeland K, Arslanian S, Cuttler L, Nathan DM, Tollefsen S, Wilfley D, Kaufman F. A clinical trial to maintain glycemic control in youth with type 2 diabetes. N Engl J Med. 2012 Jun 14;366(24):2247-56. doi: 10.1056/NEJMoa1109333. Epub 2012 Apr 29.</citation>
    <PMID>22540912</PMID>
  </results_reference>
  <results_reference>
    <citation>Kriska A, Delahanty L, Edelstein S, Amodei N, Chadwick J, Copeland K, Galvin B, El ghormli L, Haymond M, Kelsey M, Lassiter C, Mayer-Davis E, Milaszewski K, Syme A. Sedentary behavior and physical activity in youth with recent onset of type 2 diabetes. Pediatrics. 2013 Mar;131(3):e850-6. doi: 10.1542/peds.2012-0620. Epub 2013 Feb 11.</citation>
    <PMID>23400602</PMID>
  </results_reference>
  <results_reference>
    <citation>Delahanty L, Kriska A, Edelstein S, Amodei N, Chadwick J, Copeland K, Galvin B, El Ghormli L, Haymond M, Kelsey MM, Lassiter C, Milaszewski K, Syme A, Mayer-Davis E. Self-reported dietary intake of youth with recent onset of type 2 diabetes: results from the TODAY study. J Acad Nutr Diet. 2013 Mar;113(3):431-9. doi: 10.1016/j.jand.2012.11.015.</citation>
    <PMID>23438494</PMID>
  </results_reference>
  <results_reference>
    <citation>TODAY Study Group. Rapid rise in hypertension and nephropathy in youth with type 2 diabetes: the TODAY clinical trial. Diabetes Care. 2013 Jun;36(6):1735-41. doi: 10.2337/dc12-2420. Erratum in: Diabetes Care. 2013 Aug;36(8):2448.</citation>
    <PMID>23704672</PMID>
  </results_reference>
  <results_reference>
    <citation>TODAY Study Group. Treatment effects on measures of body composition in the TODAY clinical trial. Diabetes Care. 2013 Jun;36(6):1742-8. doi: 10.2337/dc12-2534.</citation>
    <PMID>23704673</PMID>
  </results_reference>
  <results_reference>
    <citation>Baldi JC, Manning PJ, Hofman PL, Walker RJ. Comment on: TODAY Study Group. Effects of metformin, metformin plus rosiglitazone, and metformin plus lifestyle on insulin sensitivity and β-cell function in TODAY. Diabetes Care 2013;36:1749-1757. Diabetes Care. 2013 Dec;36(12):e223. doi: 10.2337/dc13-1426.</citation>
    <PMID>24265392</PMID>
  </results_reference>
  <results_reference>
    <citation>TODAY Study Group. Lipid and inflammatory cardiovascular risk worsens over 3 years in youth with type 2 diabetes: the TODAY clinical trial. Diabetes Care. 2013 Jun;36(6):1758-64. doi: 10.2337/dc12-2388.</citation>
    <PMID>23704675</PMID>
  </results_reference>
  <results_reference>
    <citation>TODAY Study Group. Safety and tolerability of the treatment of youth-onset type 2 diabetes: the TODAY experience. Diabetes Care. 2013 Jun;36(6):1765-71. doi: 10.2337/dc12-2390.</citation>
    <PMID>23704676</PMID>
  </results_reference>
  <results_reference>
    <citation>TODAY Study Group. Retinopathy in youth with type 2 diabetes participating in the TODAY clinical trial. Diabetes Care. 2013 Jun;36(6):1772-4. doi: 10.2337/dc12-2387.</citation>
    <PMID>23704677</PMID>
  </results_reference>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 8, 2004</study_first_submitted>
  <study_first_submitted_qc>April 9, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 12, 2004</study_first_posted>
  <results_first_submitted>September 26, 2014</results_first_submitted>
  <results_first_submitted_qc>December 8, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 16, 2014</results_first_posted>
  <last_update_submitted>March 27, 2017</last_update_submitted>
  <last_update_submitted_qc>March 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>George Washington University</investigator_affiliation>
    <investigator_full_name>Kimberly</investigator_full_name>
    <investigator_title>Principal Investigator of Coordinating Center</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosiglitazone</mesh_term>
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were recruited from July 2004 to February 2009. Participants were recruited from the patient populations of pediatric endocrine clinics at the participating study clinical centers, including satellite clinics. Posters announced the study. Study staff approached youth and their families during medical visits.</recruitment_details>
      <pre_assignment_details>Prior to randomization, eligible subjects entered a 2-6 month run-in period, with goals of weaning from non-study diabetes medications, tolerating metformin at 1000 mg bid but no less than 500 mg bid, attaining glycemic control on metformin alone, mastering standard diabetes education, and adhering to study medication and visit attendance.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>1 Metformin Alone</title>
          <description>Metformin alone
Metformin: capsule, 1000 mg bid, provided encapsulated in weekly packets</description>
        </group>
        <group group_id="P2">
          <title>2 Metformin + Rosliglitazone</title>
          <description>Metformin + Rosiglitazone
Metformin: capsule, 1000 mg bid
Rosiglitazone: capsule, 4 mg bid, provided encapsulated in weekly packets</description>
        </group>
        <group group_id="P3">
          <title>3 Metformin + Lifestyle Program</title>
          <description>Metformin + Lifestyle Program
Metformin: capsule, 1000 mg bid, encapsulated, provided in weekly packets
Lifestyle Program: a lifestyle change (LC) phase of weekly sessions for months 1-6, followed by a bi-weekly lifestyle maintenance (LM) phase through months 7-12, and a continued contact (CC) phase from months 13 through the end of the study. The CC phase sessions are scheduled monthly for the initial 12 months (study months 13-24) and then quarterly or 4 times a year to the end of the study</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="232"/>
                <participants group_id="P2" count="233"/>
                <participants group_id="P3" count="234"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="232"/>
                <participants group_id="P2" count="233"/>
                <participants group_id="P3" count="234"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Age 10–17 years with T2D according to American Diabetes Association criteria for less than 2 years, body mass index (BMI) &gt;=85th percentile, negative diabetes autoantibodies, fasting c-peptide &gt;0.6 ng/mL, and an adult caregiver willing to actively support study participation.</population>
      <group_list>
        <group group_id="B1">
          <title>1 Metformin Alone</title>
          <description>Metformin alone
Metformin: capsule, 1000 mg bid</description>
        </group>
        <group group_id="B2">
          <title>2 Metformin + Rosiglitazone</title>
          <description>Metformin + Rosiglitazone
Metformin: capsule, 1000 mg bid
Rosiglitazone: capsule, 4 mg bid</description>
        </group>
        <group group_id="B3">
          <title>3 Metformin + Lifestyle Program</title>
          <description>Metformin + Lifestyle Program
Metformin: capsule, 1000 mg bid
Lifestyle Program: a lifestyle change (LC) phase of weekly sessions for months 1-6, followed by a bi-weekly lifestyle maintenance (LM) phase through months 7-12, and a continued contact (CC) phase from months 13 through the end of the study. The CC phase sessions are scheduled monthly for the initial 12 months (study months 13-24) and then quarterly or 4 times a year to the end of the study</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="232"/>
            <count group_id="B2" value="233"/>
            <count group_id="B3" value="234"/>
            <count group_id="B4" value="699"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14.1" spread="1.9"/>
                    <measurement group_id="B2" value="14.1" spread="2.1"/>
                    <measurement group_id="B3" value="13.8" spread="2.0"/>
                    <measurement group_id="B4" value="14.0" spread="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="146"/>
                    <measurement group_id="B2" value="152"/>
                    <measurement group_id="B3" value="154"/>
                    <measurement group_id="B4" value="452"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="86"/>
                    <measurement group_id="B2" value="81"/>
                    <measurement group_id="B3" value="80"/>
                    <measurement group_id="B4" value="247"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black Non-Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="77"/>
                    <measurement group_id="B2" value="64"/>
                    <measurement group_id="B3" value="86"/>
                    <measurement group_id="B4" value="227"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="91"/>
                    <measurement group_id="B2" value="101"/>
                    <measurement group_id="B3" value="86"/>
                    <measurement group_id="B4" value="278"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White Non-Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                    <measurement group_id="B2" value="47"/>
                    <measurement group_id="B3" value="46"/>
                    <measurement group_id="B4" value="142"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian Non-Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="232"/>
                    <measurement group_id="B2" value="233"/>
                    <measurement group_id="B3" value="234"/>
                    <measurement group_id="B4" value="699"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body mass index z-score</title>
          <units>z-score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.27" spread="0.45"/>
                    <measurement group_id="B2" value="2.22" spread="0.49"/>
                    <measurement group_id="B3" value="2.18" spread="0.46"/>
                    <measurement group_id="B4" value="2.23" spread="0.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Percent overweight</title>
          <units>100% X (BMI-50th %ile)/50th %ile</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="82.1" spread="38.3"/>
                    <measurement group_id="B2" value="79.1" spread="38.1"/>
                    <measurement group_id="B3" value="75.6" spread="35.3"/>
                    <measurement group_id="B4" value="78.9" spread="37.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Duration of diabetes</title>
          <units>months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.8" spread="6.0"/>
                    <measurement group_id="B2" value="8.0" spread="5.7"/>
                    <measurement group_id="B3" value="7.6" spread="5.8"/>
                    <measurement group_id="B4" value="7.8" spread="5.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Total annual household income</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt; $25,000</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="81"/>
                    <measurement group_id="B2" value="86"/>
                    <measurement group_id="B3" value="92"/>
                    <measurement group_id="B4" value="259"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>$25,000-49,999</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="83"/>
                    <measurement group_id="B2" value="61"/>
                    <measurement group_id="B3" value="66"/>
                    <measurement group_id="B4" value="210"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=$50,000</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="58"/>
                    <measurement group_id="B3" value="53"/>
                    <measurement group_id="B4" value="155"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="23"/>
                    <measurement group_id="B4" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Highest household education level</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Less than high school</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                    <measurement group_id="B2" value="60"/>
                    <measurement group_id="B3" value="62"/>
                    <measurement group_id="B4" value="182"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High school, GED, business or technical</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57"/>
                    <measurement group_id="B2" value="49"/>
                    <measurement group_id="B3" value="66"/>
                    <measurement group_id="B4" value="172"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>College no degree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="77"/>
                    <measurement group_id="B2" value="78"/>
                    <measurement group_id="B3" value="63"/>
                    <measurement group_id="B4" value="218"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Graduate degree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="38"/>
                    <measurement group_id="B4" value="114"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Tanner stage by physical examination</title>
          <description>Tanner stage is a standard 5-point scale of pubertal maturity from 1 (pre-pubertal) to 5 (post-pubertal).</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>4 or 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="209"/>
                    <measurement group_id="B2" value="207"/>
                    <measurement group_id="B3" value="204"/>
                    <measurement group_id="B4" value="620"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1, 2, or 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="30"/>
                    <measurement group_id="B4" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Nuclear family history of diabetes</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="97"/>
                    <measurement group_id="B2" value="93"/>
                    <measurement group_id="B3" value="86"/>
                    <measurement group_id="B4" value="276"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="131"/>
                    <measurement group_id="B2" value="133"/>
                    <measurement group_id="B3" value="143"/>
                    <measurement group_id="B4" value="407"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Nuclear family + grandparents history of diabetes</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="29"/>
                    <measurement group_id="B4" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="211"/>
                    <measurement group_id="B2" value="200"/>
                    <measurement group_id="B3" value="200"/>
                    <measurement group_id="B4" value="611"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Insulin sensitivity (inverse of fasting insulin from OGTT)</title>
          <units>mL/uU</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value=".036" lower_limit=".025" upper_limit=".050"/>
                    <measurement group_id="B2" value=".040" lower_limit=".028" upper_limit=".064"/>
                    <measurement group_id="B3" value=".040" lower_limit=".027" upper_limit=".067"/>
                    <measurement group_id="B4" value=".039" lower_limit=".027" upper_limit=".060"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Insulinogenic index from OGTT</title>
          <units>uU/mL divided by mg/dL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.02" lower_limit=".47" upper_limit="1.98"/>
                    <measurement group_id="B2" value=".92" lower_limit=".47" upper_limit="1.58"/>
                    <measurement group_id="B3" value=".87" lower_limit=".47" upper_limit="1.89"/>
                    <measurement group_id="B4" value=".93" lower_limit=".47" upper_limit="1.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body mass index (BMI)</title>
          <units>kg per m squared</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35.8" spread="8.1"/>
                    <measurement group_id="B2" value="35.0" spread="7.7"/>
                    <measurement group_id="B3" value="34.1" spread="7.1"/>
                    <measurement group_id="B4" value="34.9" spread="7.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Waist circumference</title>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="110.4" spread="16.6"/>
                    <measurement group_id="B2" value="109.0" spread="17.0"/>
                    <measurement group_id="B3" value="106.6" spread="16.2"/>
                    <measurement group_id="B4" value="108.6" spread="16.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fat mass from DXA</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33.7" spread="9.9"/>
                    <measurement group_id="B2" value="33.5" spread="10.2"/>
                    <measurement group_id="B3" value="32.6" spread="9.8"/>
                    <measurement group_id="B4" value="33.3" spread="10.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Bone density from DXA</title>
          <units>g per cm squared</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.09" spread=".12"/>
                    <measurement group_id="B2" value="1.10" spread=".13"/>
                    <measurement group_id="B3" value="1.08" spread=".12"/>
                    <measurement group_id="B4" value="1.09" spread=".13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Treatment Failure (Loss of Glycemic Control)</title>
        <description>Defined as A1c persistently &gt;=8% over a 6-month period or persistent metabolic decompensation (inability to wean insulin within 3 months of initiation or the occurrence of a second episode within three months of discontinuing insulin)</description>
        <time_frame>Study duration - 2 years to 6.5 years of follow up from randomization</time_frame>
        <population>The entire cohort of 699 participants was included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>1 Metformin Alone</title>
            <description>Metformin alone
Metformin: capsule, 1000 mg bid</description>
          </group>
          <group group_id="O2">
            <title>2 Metformin + Rosliglitazone</title>
            <description>Metformin + Rosiglitazone
Metformin: capsule, 1000 mg bid
Rosiglitazone: capsule, 4 mg bid</description>
          </group>
          <group group_id="O3">
            <title>3 Metformin + Lifestyle Program</title>
            <description>Metformin + Lifestyle Program
Metformin: capsule, 1000 mg bid
Lifestyle Program: a lifestyle change (LC) phase of weekly sessions for months 1-6, followed by a bi-weekly lifestyle maintenance (LM) phase through months 7-12, and a continued contact (CC) phase from months 13 through the end of the study. The CC phase sessions are scheduled monthly for the initial 12 months (study months 13-24) and then quarterly or 4 times a year to the end of the study</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment Failure (Loss of Glycemic Control)</title>
          <description>Defined as A1c persistently &gt;=8% over a 6-month period or persistent metabolic decompensation (inability to wean insulin within 3 months of initiation or the occurrence of a second episode within three months of discontinuing insulin)</description>
          <population>The entire cohort of 699 participants was included in the analysis.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="232"/>
                <count group_id="O2" value="233"/>
                <count group_id="O3" value="234"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Treatment failure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="120"/>
                    <measurement group_id="O2" value="90"/>
                    <measurement group_id="O3" value="109"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Did not fail treatment during trial</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="112"/>
                    <measurement group_id="O2" value="143"/>
                    <measurement group_id="O3" value="125"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Insulin Sensitivity</title>
        <description>All participants were followed to 24 months. Insulin sensitivity is measured from OGTT as inverse of fasting insulin (mL/uU). The analysis sample includes only participants with 24 month data who had not experienced the primary outcome by that time.</description>
        <time_frame>24 months</time_frame>
        <population>Participants who were measured at 24 months and had not experienced treatment failure.</population>
        <group_list>
          <group group_id="O1">
            <title>1 Metformin Alone</title>
            <description>Metformin alone
Metformin: capsule, 1000 mg bid</description>
          </group>
          <group group_id="O2">
            <title>2 Metformin + Rosiglitazone</title>
            <description>Metformin + Rosiglitazone
Metformin: capsule, 1000 mg bid
Rosiglitazone: capsule, 4 mg bid</description>
          </group>
          <group group_id="O3">
            <title>3 Metformin + Lifestyle Program</title>
            <description>Metformin + Lifestyle Program
Metformin: capsule, 1000 mg bid
Lifestyle Program: a lifestyle change (LC) phase of weekly sessions for months 1-6, followed by a bi-weekly lifestyle maintenance (LM) phase through months 7-12, and a continued contact (CC) phase from months 13 through the end of the study. The CC phase sessions are scheduled monthly for the initial 12 months (study months 13-24) and then quarterly or 4 times a year to the end of the study</description>
          </group>
        </group_list>
        <measure>
          <title>Insulin Sensitivity</title>
          <description>All participants were followed to 24 months. Insulin sensitivity is measured from OGTT as inverse of fasting insulin (mL/uU). The analysis sample includes only participants with 24 month data who had not experienced the primary outcome by that time.</description>
          <population>Participants who were measured at 24 months and had not experienced treatment failure.</population>
          <units>mL/uU</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="167"/>
                <count group_id="O2" value="157"/>
                <count group_id="O3" value="167"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.037" lower_limit="0.023" upper_limit="0.061"/>
                    <measurement group_id="O2" value="0.049" lower_limit="0.031" upper_limit="0.068"/>
                    <measurement group_id="O3" value="0.039" lower_limit="0.027" upper_limit="0.064"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety</title>
        <description>Number of serious adverse events reported during the trial. Participant could have multiple episodes reported.</description>
        <time_frame>Reported as occurred during study follow-up - 2 years to 6.5 years from randomization.</time_frame>
        <population>Entire cohort.</population>
        <group_list>
          <group group_id="O1">
            <title>1 Metformin Alone</title>
            <description>Metformin alone
Metformin: capsule, 1000 mg bid</description>
          </group>
          <group group_id="O2">
            <title>2 Metformin + Rosiglitazone</title>
            <description>Metformin + Rosiglitazone
Metformin: capsule, 1000 mg bid
Rosiglitazone: capsule, 4 mg bid</description>
          </group>
          <group group_id="O3">
            <title>3 Metformin + Lifestyle Program</title>
            <description>Metformin + Lifestyle Program
Metformin: capsule, 1000 mg bid
Lifestyle Program: a lifestyle change (LC) phase of weekly sessions for months 1-6, followed by a bi-weekly lifestyle maintenance (LM) phase through months 7-12, and a continued contact (CC) phase from months 13 through the end of the study. The CC phase sessions are scheduled monthly for the initial 12 months (study months 13-24) and then quarterly or 4 times a year to the end of the study</description>
          </group>
        </group_list>
        <measure>
          <title>Safety</title>
          <description>Number of serious adverse events reported during the trial. Participant could have multiple episodes reported.</description>
          <population>Entire cohort.</population>
          <units>episodes of serious adverse event</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="232"/>
                <count group_id="O2" value="233"/>
                <count group_id="O3" value="234"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                    <measurement group_id="O2" value="34"/>
                    <measurement group_id="O3" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Insulin Secretion</title>
        <description>Insulinogenic index determined from OGTT as difference in insulin at 30 minutes minus 0 minutes divided by difference in glucose at 30 minutes minus 0 minutes. The analysis sample includes only participants with 24 month data who had not experienced the primary outcome by that time.</description>
        <time_frame>24 months</time_frame>
        <population>Participants who were measured at 24 months and had not experience treatment failure.</population>
        <group_list>
          <group group_id="O1">
            <title>1 Metformin Alone</title>
            <description>Metformin alone
Metformin: capsule, 1000 mg bid</description>
          </group>
          <group group_id="O2">
            <title>2 Metformin + Rosliglitazone</title>
            <description>Metformin + Rosiglitazone
Metformin: capsule, 1000 mg bid
Rosiglitazone: capsule, 4 mg bid</description>
          </group>
          <group group_id="O3">
            <title>3 Metformin + Lifestyle Program</title>
            <description>Metformin + Lifestyle Program
Metformin: capsule, 1000 mg bid
Lifestyle Program: a lifestyle change (LC) phase of weekly sessions for months 1-6, followed by a bi-weekly lifestyle maintenance (LM) phase through months 7-12, and a continued contact (CC) phase from months 13 through the end of the study. The CC phase sessions are scheduled monthly for the initial 12 months (study months 13-24) and then quarterly or 4 times a year to the end of the study</description>
          </group>
        </group_list>
        <measure>
          <title>Insulin Secretion</title>
          <description>Insulinogenic index determined from OGTT as difference in insulin at 30 minutes minus 0 minutes divided by difference in glucose at 30 minutes minus 0 minutes. The analysis sample includes only participants with 24 month data who had not experienced the primary outcome by that time.</description>
          <population>Participants who were measured at 24 months and had not experience treatment failure.</population>
          <units>uU/mL divided by mg/dL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="150"/>
                <count group_id="O2" value="147"/>
                <count group_id="O3" value="155"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".75" lower_limit=".33" upper_limit="1.39"/>
                    <measurement group_id="O2" value=".83" lower_limit=".28" upper_limit="1.38"/>
                    <measurement group_id="O3" value=".71" lower_limit=".26" upper_limit="1.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Body Composition -- BMI</title>
        <description>Body mass index (BMI) measured in kg per meters squared. The analysis sample includes only participants with 24 month data who had not experienced the primary outcome by that time.</description>
        <time_frame>24 months</time_frame>
        <population>Cohort measured at 24 months and had not experienced treatment failure.</population>
        <group_list>
          <group group_id="O1">
            <title>1 Metformin Alone</title>
            <description>Metformin alone
Metformin: capsule, 1000 mg bid</description>
          </group>
          <group group_id="O2">
            <title>2 Metformin + Rosliglitazone</title>
            <description>Metformin + Rosiglitazone
Metformin: capsule, 1000 mg bid
Rosiglitazone: capsule, 4 mg bid</description>
          </group>
          <group group_id="O3">
            <title>3 Metformin + Lifestyle Program</title>
            <description>Metformin + Lifestyle Program
Metformin: capsule, 1000 mg bid
Lifestyle Program: a lifestyle change (LC) phase of weekly sessions for months 1-6, followed by a bi-weekly lifestyle maintenance (LM) phase through months 7-12, and a continued contact (CC) phase from months 13 through the end of the study. The CC phase sessions are scheduled monthly for the initial 12 months (study months 13-24) and then quarterly or 4 times a year to the end of the study</description>
          </group>
        </group_list>
        <measure>
          <title>Body Composition -- BMI</title>
          <description>Body mass index (BMI) measured in kg per meters squared. The analysis sample includes only participants with 24 month data who had not experienced the primary outcome by that time.</description>
          <population>Cohort measured at 24 months and had not experienced treatment failure.</population>
          <units>kg per meters squared</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="132"/>
                <count group_id="O2" value="138"/>
                <count group_id="O3" value="134"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.7" spread="9.1"/>
                    <measurement group_id="O2" value="38.2" spread="8.1"/>
                    <measurement group_id="O3" value="35.3" spread="8.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Body Composition -- Waist Circumference</title>
        <description>Waist circumference (cm) measured at the iliac crest at its outermost point with the measuring tape placed around the participant in a horizontal plane parallel to the floor at the mark and the measurement teken at the end of normal expiration without the tape compressing the skin. The analysis sample includes only participants with 24 month data who had not experienced the primary outcome by that time.</description>
        <time_frame>24 months</time_frame>
        <population>Members of cohort measured at 24 months who had not experience treatment failure.</population>
        <group_list>
          <group group_id="O1">
            <title>1 Metformin Alone</title>
            <description>Metformin alone
Metformin: capsule, 1000 mg bid</description>
          </group>
          <group group_id="O2">
            <title>2 Metformin + Rosliglitazone</title>
            <description>Metformin + Rosiglitazone
Metformin: capsule, 1000 mg bid
Rosiglitazone: capsule, 4 mg bid</description>
          </group>
          <group group_id="O3">
            <title>3 Metformin + Lifestyle Program</title>
            <description>Metformin + Lifestyle Program
Metformin: capsule, 1000 mg bid
Lifestyle Program: a lifestyle change (LC) phase of weekly sessions for months 1-6, followed by a bi-weekly lifestyle maintenance (LM) phase through months 7-12, and a continued contact (CC) phase from months 13 through the end of the study. The CC phase sessions are scheduled monthly for the initial 12 months (study months 13-24) and then quarterly or 4 times a year to the end of the study</description>
          </group>
        </group_list>
        <measure>
          <title>Body Composition -- Waist Circumference</title>
          <description>Waist circumference (cm) measured at the iliac crest at its outermost point with the measuring tape placed around the participant in a horizontal plane parallel to the floor at the mark and the measurement teken at the end of normal expiration without the tape compressing the skin. The analysis sample includes only participants with 24 month data who had not experienced the primary outcome by that time.</description>
          <population>Members of cohort measured at 24 months who had not experience treatment failure.</population>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="132"/>
                <count group_id="O2" value="138"/>
                <count group_id="O3" value="134"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="110.8" spread="17.5"/>
                    <measurement group_id="O2" value="114.0" spread="16.3"/>
                    <measurement group_id="O3" value="108.6" spread="16.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Body Composition -- Bone Density</title>
        <description>Measured by DXA, both whole body scan and AP-spine scan. The analysis sample includes only participants with 24 month data who had not experienced the primary outcome by that time. In addition, in about 1/3 of participants DXA scans could not be obtained on participants weighing more than 300 pounds (136 kg), the upper limit in size set by the machine manufacturers. Scans were considered invalid if a body part (e.g., arm, leg) was completely off or partially off the scanner, there was hand-hip overlap, or there was motion or movement during the scan.</description>
        <time_frame>24 months</time_frame>
        <population>Members of the cohort measured at 24 months who did not experience treatment failure.</population>
        <group_list>
          <group group_id="O1">
            <title>1 Metformin Alone</title>
            <description>Metformin alone
Metformin: capsule, 1000 mg bid</description>
          </group>
          <group group_id="O2">
            <title>2 Metformin + Rosliglitazone</title>
            <description>Metformin + Rosiglitazone
Metformin: capsule, 1000 mg bid
Rosiglitazone: capsule, 4 mg bid</description>
          </group>
          <group group_id="O3">
            <title>3 Metformin + Lifestyle Program</title>
            <description>Metformin + Lifestyle Program
Metformin: capsule, 1000 mg bid
Lifestyle Program: a lifestyle change (LC) phase of weekly sessions for months 1-6, followed by a bi-weekly lifestyle maintenance (LM) phase through months 7-12, and a continued contact (CC) phase from months 13 through the end of the study. The CC phase sessions are scheduled monthly for the initial 12 months (study months 13-24) and then quarterly or 4 times a year to the end of the study</description>
          </group>
        </group_list>
        <measure>
          <title>Body Composition -- Bone Density</title>
          <description>Measured by DXA, both whole body scan and AP-spine scan. The analysis sample includes only participants with 24 month data who had not experienced the primary outcome by that time. In addition, in about 1/3 of participants DXA scans could not be obtained on participants weighing more than 300 pounds (136 kg), the upper limit in size set by the machine manufacturers. Scans were considered invalid if a body part (e.g., arm, leg) was completely off or partially off the scanner, there was hand-hip overlap, or there was motion or movement during the scan.</description>
          <population>Members of the cohort measured at 24 months who did not experience treatment failure.</population>
          <units>g/cm squared</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="132"/>
                <count group_id="O2" value="138"/>
                <count group_id="O3" value="134"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.15" spread=".10"/>
                    <measurement group_id="O2" value="1.15" spread=".11"/>
                    <measurement group_id="O3" value="1.15" spread=".12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Body Composition -- Fat Mass</title>
        <description>Determined by DXA whole body scan. The analysis sample includes only participants with 24 month data who had not experienced the primary outcome by that time. In addition, in about 1/3 of participants DXA scans could not be obtained on participants weighing more than 300 pounds (136 kg), the upper limit in size set by the machine manufacturers. Scans were considered invalid if a body part (e.g., arm, leg) was completely off or partially off the scanner, there was hand-hip overlap, or there was motion or movement during the scan.</description>
        <time_frame>24 months</time_frame>
        <population>Members of the cohort measured at 24 months who did not experience treatment failure.</population>
        <group_list>
          <group group_id="O1">
            <title>1 Metformin Alone</title>
            <description>Metformin alone
Metformin: capsule, 1000 mg bid</description>
          </group>
          <group group_id="O2">
            <title>2 Metformin + Rosliglitazone</title>
            <description>Metformin + Rosiglitazone
Metformin: capsule, 1000 mg bid
Rosiglitazone: capsule, 4 mg bid</description>
          </group>
          <group group_id="O3">
            <title>3 Metformin + Lifestyle Program</title>
            <description>Metformin + Lifestyle Program
Metformin: capsule, 1000 mg bid
Lifestyle Program: a lifestyle change (LC) phase of weekly sessions for months 1-6, followed by a bi-weekly lifestyle maintenance (LM) phase through months 7-12, and a continued contact (CC) phase from months 13 through the end of the study. The CC phase sessions are scheduled monthly for the initial 12 months (study months 13-24) and then quarterly or 4 times a year to the end of the study</description>
          </group>
        </group_list>
        <measure>
          <title>Body Composition -- Fat Mass</title>
          <description>Determined by DXA whole body scan. The analysis sample includes only participants with 24 month data who had not experienced the primary outcome by that time. In addition, in about 1/3 of participants DXA scans could not be obtained on participants weighing more than 300 pounds (136 kg), the upper limit in size set by the machine manufacturers. Scans were considered invalid if a body part (e.g., arm, leg) was completely off or partially off the scanner, there was hand-hip overlap, or there was motion or movement during the scan.</description>
          <population>Members of the cohort measured at 24 months who did not experience treatment failure.</population>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="132"/>
                <count group_id="O2" value="138"/>
                <count group_id="O3" value="134"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.1" spread="12.0"/>
                    <measurement group_id="O2" value="39.7" spread="10.5"/>
                    <measurement group_id="O3" value="32.2" spread="9.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Comorbidity -- Hypertension</title>
        <description>A diagnosis was made by an out-of-range value &gt;=95th percentile or systolic &gt;=130 or diastolic &gt;=80 sustained over 6 months or on an anti-hypertensive medication.</description>
        <time_frame>Data collected at baseline and during follow-up - 2 years to 6.5 years from randomization.</time_frame>
        <population>Entire cohort.</population>
        <group_list>
          <group group_id="O1">
            <title>1 Metformin Alone</title>
            <description>Metformin alone
Metformin: capsule, 1000 mg bid</description>
          </group>
          <group group_id="O2">
            <title>2 Metformin + Rosliglitazone</title>
            <description>Metformin + Rosiglitazone
Metformin: capsule, 1000 mg bid
Rosiglitazone: capsule, 4 mg bid</description>
          </group>
          <group group_id="O3">
            <title>3 Metformin + Lifestyle Program</title>
            <description>Metformin + Lifestyle Program
Metformin: capsule, 1000 mg bid
Lifestyle Program: a lifestyle change (LC) phase of weekly sessions for months 1-6, followed by a bi-weekly lifestyle maintenance (LM) phase through months 7-12, and a continued contact (CC) phase from months 13 through the end of the study. The CC phase sessions are scheduled monthly for the initial 12 months (study months 13-24) and then quarterly or 4 times a year to the end of the study</description>
          </group>
        </group_list>
        <measure>
          <title>Comorbidity -- Hypertension</title>
          <description>A diagnosis was made by an out-of-range value &gt;=95th percentile or systolic &gt;=130 or diastolic &gt;=80 sustained over 6 months or on an anti-hypertensive medication.</description>
          <population>Entire cohort.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="232"/>
                <count group_id="O2" value="233"/>
                <count group_id="O3" value="234"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57"/>
                    <measurement group_id="O2" value="53"/>
                    <measurement group_id="O3" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Comorbidity -- LDL Dyslipidemia</title>
        <description>A diagnosis was made from out-of-range value &gt;= 130 mg/dL sustained over 6 months or put on lipid lowering medication.</description>
        <time_frame>Data collected at baseline and during follow-up - 2 years to 6.5 years from randomization.</time_frame>
        <population>Entire cohort.</population>
        <group_list>
          <group group_id="O1">
            <title>1 Metformin Alone</title>
            <description>Metformin alone
Metformin: capsule, 1000 mg bid</description>
          </group>
          <group group_id="O2">
            <title>2 Metformin + Rosliglitazone</title>
            <description>Metformin + Rosiglitazone
Metformin: capsule, 1000 mg bid
Rosiglitazone: capsule, 4 mg bid</description>
          </group>
          <group group_id="O3">
            <title>3 Metformin + Lifestyle Program</title>
            <description>Metformin + Lifestyle Program
Metformin: capsule, 1000 mg bid
Lifestyle Program: a lifestyle change (LC) phase of weekly sessions for months 1-6, followed by a bi-weekly lifestyle maintenance (LM) phase through months 7-12, and a continued contact (CC) phase from months 13 through the end of the study. The CC phase sessions are scheduled monthly for the initial 12 months (study months 13-24) and then quarterly or 4 times a year to the end of the study</description>
          </group>
        </group_list>
        <measure>
          <title>Comorbidity -- LDL Dyslipidemia</title>
          <description>A diagnosis was made from out-of-range value &gt;= 130 mg/dL sustained over 6 months or put on lipid lowering medication.</description>
          <population>Entire cohort.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="232"/>
                <count group_id="O2" value="233"/>
                <count group_id="O3" value="234"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Comorbidity -- Triglycerides Dyslipidemia</title>
        <description>A diagnosis was made by an out-of-range value &gt;=150 mg/dL sustained over 6 months or on appropriate lipid lowering medication.</description>
        <time_frame>Data collected at baseline and during follow-up - 2 years to 6.5 years from randomization.</time_frame>
        <population>Entire cohort.</population>
        <group_list>
          <group group_id="O1">
            <title>1 Metformin Alone</title>
            <description>Metformin alone
Metformin: capsule, 1000 mg bid</description>
          </group>
          <group group_id="O2">
            <title>2 Metformin + Rosliglitazone</title>
            <description>Metformin + Rosiglitazone
Metformin: capsule, 1000 mg bid
Rosiglitazone: capsule, 4 mg bid</description>
          </group>
          <group group_id="O3">
            <title>3 Metformin + Lifestyle Program</title>
            <description>Metformin + Lifestyle Program
Metformin: capsule, 1000 mg bid
Lifestyle Program: a lifestyle change (LC) phase of weekly sessions for months 1-6, followed by a bi-weekly lifestyle maintenance (LM) phase through months 7-12, and a continued contact (CC) phase from months 13 through the end of the study. The CC phase sessions are scheduled monthly for the initial 12 months (study months 13-24) and then quarterly or 4 times a year to the end of the study</description>
          </group>
        </group_list>
        <measure>
          <title>Comorbidity -- Triglycerides Dyslipidemia</title>
          <description>A diagnosis was made by an out-of-range value &gt;=150 mg/dL sustained over 6 months or on appropriate lipid lowering medication.</description>
          <population>Entire cohort.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="232"/>
                <count group_id="O2" value="233"/>
                <count group_id="O3" value="234"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="28"/>
                    <measurement group_id="O3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>During the 2-6 month pre-randomization run-in period and during follow-up from 2-6.5 years.</time_frame>
      <desc>Terminology and criteria standard for clinical trials conducted by NIH were used.</desc>
      <group_list>
        <group group_id="E1">
          <title>1 Metformin Alone</title>
          <description>Metformin alone
Metformin: capsule, 1000 mg bid</description>
        </group>
        <group group_id="E2">
          <title>2 Metformin + Rosliglitazone</title>
          <description>Metformin + Rosiglitazone
Metformin: capsule, 1000 mg bid
Rosiglitazone: capsule, 4 mg bid</description>
        </group>
        <group group_id="E3">
          <title>3 Metformin + Lifestyle Program</title>
          <description>Metformin + Lifestyle Program
Metformin: capsule, 1000 mg bid
Lifestyle Program: a lifestyle change (LC) phase of weekly sessions for months 1-6, followed by a bi-weekly lifestyle maintenance (LM) phase through months 7-12, and a continued contact (CC) phase from months 13 through the end of the study. The CC phase sessions are scheduled monthly for the initial 12 months (study months 13-24) and then quarterly or 4 times a year to the end of the study</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="232"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="233"/>
                <counts group_id="E3" subjects_affected="58" subjects_at_risk="234"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetic ketoacidosis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="232"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="233"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="234"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="232"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="233"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="234"/>
              </event>
              <event>
                <sub_title>Hypoglycemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="232"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="233"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="234"/>
              </event>
              <event>
                <sub_title>Lactic acidosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="232"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="233"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="234"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>all other</sub_title>
                <counts group_id="E1" events="32" subjects_affected="32" subjects_at_risk="232"/>
                <counts group_id="E2" events="25" subjects_affected="25" subjects_at_risk="233"/>
                <counts group_id="E3" events="51" subjects_affected="51" subjects_at_risk="234"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="215" subjects_at_risk="232"/>
                <counts group_id="E2" subjects_affected="196" subjects_at_risk="233"/>
                <counts group_id="E3" subjects_affected="213" subjects_at_risk="234"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycemia symptoms</sub_title>
                <description>Symptoms of diabetes out of control included nocturia more than once a night on a regular basis, enuresis, increased thirst, urinating more often than usual.</description>
                <counts group_id="E1" events="115" subjects_affected="115" subjects_at_risk="232"/>
                <counts group_id="E2" events="98" subjects_affected="98" subjects_at_risk="233"/>
                <counts group_id="E3" events="103" subjects_affected="103" subjects_at_risk="234"/>
              </event>
              <event>
                <sub_title>Mild hypoglycemia</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="232"/>
                <counts group_id="E2" events="19" subjects_affected="19" subjects_at_risk="233"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="234"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal symptoms</sub_title>
                <description>Frequent stomach pains, bloating, nausea, diarrhea, or loss of appetite.</description>
                <counts group_id="E1" events="129" subjects_affected="129" subjects_at_risk="232"/>
                <counts group_id="E2" events="100" subjects_affected="100" subjects_at_risk="233"/>
                <counts group_id="E3" events="136" subjects_affected="136" subjects_at_risk="234"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection requiring medical attention</sub_title>
                <counts group_id="E1" events="149" subjects_affected="149" subjects_at_risk="232"/>
                <counts group_id="E2" events="120" subjects_affected="120" subjects_at_risk="233"/>
                <counts group_id="E3" events="151" subjects_affected="151" subjects_at_risk="234"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Sprain or fracture requiring medical attention</sub_title>
                <counts group_id="E1" events="66" subjects_affected="66" subjects_at_risk="232"/>
                <counts group_id="E2" events="53" subjects_affected="53" subjects_at_risk="233"/>
                <counts group_id="E3" events="64" subjects_affected="64" subjects_at_risk="234"/>
              </event>
              <event>
                <sub_title>Muscle ache or pain</sub_title>
                <counts group_id="E1" events="68" subjects_affected="68" subjects_at_risk="232"/>
                <counts group_id="E2" events="53" subjects_affected="53" subjects_at_risk="233"/>
                <counts group_id="E3" events="77" subjects_affected="77" subjects_at_risk="234"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin rash on physical examination</sub_title>
                <counts group_id="E1" events="108" subjects_affected="108" subjects_at_risk="232"/>
                <counts group_id="E2" events="101" subjects_affected="101" subjects_at_risk="233"/>
                <counts group_id="E3" events="95" subjects_affected="95" subjects_at_risk="234"/>
              </event>
              <event>
                <sub_title>Edema on physical examination</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="232"/>
                <counts group_id="E2" events="17" subjects_affected="17" subjects_at_risk="233"/>
                <counts group_id="E3" events="17" subjects_affected="17" subjects_at_risk="234"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>This work was conducted by a collaborative group. All investigators in the study group adhere to the Publications &amp; Presentations Policy. The policy spells out procedures for proposing, developing, and submitting publications and presentations using study data. Once results have been published or presented, all members of the study group are free to discuss them.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Kathryn Hirst, Coordinating Center PI</name_or_title>
      <organization>TODAY Coordinating Center at George Washington University Biostatistics Center</organization>
      <phone>301-881-9260 ext 8025</phone>
      <email>khirst@bsc.gwu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

